Amgen CEO Robert Bradway said the company's obesity drug could find its space in the market due to once-monthly dosing and ...

Two medical spas have been sued by Eli Lilly for selling unapproved products that claim to contain tirzepatide. Tirzepatide ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...

Ozempic, inflation and the Trump presidency will likely dictate food waste trends in the US in 2025, according to non-profit ...

Even though some GLP-1 medications like Wegovy and Zepbound are FDA-approved for weight loss, getting insurance companies to ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

Eli Lilly (LLY) has reportedly asked the Biden administration to pause negotiations with drugmakers over pricing, citing ...

A coalition of obesity-related patient advocacy groups is calling on the incoming Trump administration to finalize a proposal ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...